Establishment Labs, a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, amended its $225 million term loan facility with funds managed by Oaktree Capital Management.
Seres Therapeutics, a microbiome therapeutics company, entered into a new $250 million senior secured debt facility provided by funds managed by Oaktree Capital Management. Seres drew the first tranche of $110 million at closing, with three additional tranches available.
Oxford Biomedica, a gene and cell therapy group, refinanced the $85 million secured 12-month loan facility from funds managed by Oaktree Capital Management.
ADC Therapeutics completed a series of strategic transactions in which it entered into a $175 million senior secured term loan with certain funds of Owl Rock as well as settled in full the $115 million aggregate principal amount of senior secured convertible notes held by Deerfield Management.
Establishment Labs, a medical technology company focused on women’s health initially in the breast aesthetics and reconstruction market, entered into a $225 million term loan financing facility with funds managed by Oaktree Capital Management.
Oaktree Capital Management closed two separate transactions totaling $100 million in gross funding for Impel NeuroPharma, a commercial-stage pharmaceutical company. The transactions include $50 million of senior secured debt.
Innocoll Biotherapeutics, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, successfully refinanced its existing term loan facility with a $125 million term loan provided by funds managed by Oaktree Capital Management.